Ongoing Clinical Trials for Neuroendocrine Tumour of the Lung
Currently, there are 2 ongoing clinical trials investigating new treatments and diagnostic methods for neuroendocrine tumours of the lung. These studies are taking place across several European countries and are testing both therapeutic treatments and advanced imaging techniques to better understand and manage this rare type of cancer.
Clinical trial locations
- Belgium
- Denmark
- France
- Italy
- Spain
Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus
This trial is comparing two different treatment approaches for patients with neuroendocrine tumours affecting the lung and thymus. The study aims to determine which treatment is more effective at preventing the cancer from getting worse, while also evaluating safety and impact on quality of life.
Main inclusion criteria: To participate in this study, you must be at least 18 years old and have a well to moderately differentiated neuroendocrine tumour in the lung or thymus that has either spread to other parts of the body or cannot be removed by surgery. The cancer must have shown growth within the last 12 months and be measurable on scans. A tumour tissue sample must be available for testing, either from a previous biopsy taken within the last 36 months or a new sample. You need to have a good performance status, meaning you can carry out light work even if restricted from strenuous activity. Blood tests must show adequate organ and bone marrow function. Women must have a negative pregnancy test and agree to use highly effective birth control during the study and for 6 months afterwards, and must not breastfeed or donate eggs during this time. Men must agree to use condoms or practice abstinence and not donate sperm during the study and for 6 months after treatment ends. Your cancer must test positive for somatostatin receptors on imaging tests, and you should have received no more than two previous systemic anti-cancer treatments.
Main exclusion criteria: You cannot participate if your tumour is not well to moderately differentiated or if you do not require systemic therapy, which means treatment affecting the entire body.
Focus of the trial: The study is designed to compare how well two different treatments work in stopping cancer progression. The main goal is to measure progression-free survival, which is the length of time from starting treatment until the disease shows signs of getting worse or the patient passes away. Participants will be randomly assigned to receive either 177Lu-edotreotide or everolimus, and their health will be closely monitored throughout the study period with regular check-ups and assessments.
Investigational drugs: The study tests 177Lu-edotreotide, a type of peptide receptor radionuclide therapy that delivers targeted radiation to tumour cells by binding to specific receptors on their surface. It is given through intravenous infusion directly into the bloodstream. The comparison treatment is everolimus, a medication taken as a 10 mg tablet that works by blocking a protein called mTOR, which helps cancer cells grow and multiply. Both treatments aim to slow down or stop tumour growth through different mechanisms.
Study of 68Ga Satoreotide Trizoxetan PET/CT in Patients with High-Grade Neuroendocrine Lung Cancer
This trial is investigating a new imaging method for patients with high-grade neuroendocrine lung cancer, including large cell neuroendocrine lung cancer and small cell lung cancer. The study focuses on evaluating how well a new imaging tracer can help doctors see and understand the cancer better.
Main inclusion criteria: You must be at least 18 years old and have a pathologically verified diagnosis of either small cell lung cancer or large cell neuroendocrine lung cancer, which means a doctor has confirmed your cancer type through medical tests. You must provide informed consent, agreeing to participate after being fully informed about the study, both orally and in writing.
Main exclusion criteria: You cannot participate if you have any type of cancer other than large cell neuroendocrine lung cancer or small cell lung cancer. Patients who do not fall within the specified age range or who are part of a vulnerable population requiring special protection or care are also excluded.
Focus of the trial: The study aims to evaluate how well the new imaging tracer, 68Ga-satoreotide trizoxetan, is taken up by cancer cells during a PET/CT scan. Researchers will measure how much of the tracer is absorbed by cancerous areas and compare this to absorption in normal organs like the lung, kidney, liver, spleen, lymph nodes, and brain. This will help determine whether the new tracer can distinguish between cancerous and non-cancerous tissues more effectively than previous imaging methods. The study is expected to continue until mid-2026.
Investigational drug: The study uses 68Ga-satoreotide trizoxetan, a radiopharmaceutical imaging agent that is injected into the body before a PET/CT scan. This tracer travels to cancer cells and binds to specific receptors, making the cancer cells light up on the scan. This helps doctors see more clearly where the cancer is located and how much cancer is present, which can be valuable information for planning treatment. The medication is being studied specifically for its ability to detect high-grade neuroendocrine lung cancers.
Summary
The two ongoing clinical trials for neuroendocrine tumours of the lung reflect different approaches to managing this rare cancer. One trial focuses on comparing therapeutic treatments using radiation-based therapy and targeted medication, while the other investigates improved diagnostic imaging techniques. Geographically, the therapeutic trial is being conducted across multiple European countries including Belgium, Denmark, France, Italy, and Spain, while the imaging study is located solely in Denmark. Both studies target specific subtypes of neuroendocrine lung cancer, with one focusing on well to moderately differentiated tumours that are positive for somatostatin receptors, and the other addressing high-grade variants including small cell and large cell neuroendocrine lung cancer. The therapeutic trial investigates two distinct treatment mechanisms: peptide receptor radionuclide therapy with 177Lu-edotreotide and mTOR inhibition with everolimus, providing patients with potential new treatment options for managing disease progression.
